Business
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
Phase 1b study demonstrates that miricorilant, a selective cortisol modulator, effectively reduces liver fat, improves liver health and key metabolic and
About this update from Corcept Therapeutics Incorporated
[{"type":"text","content":"Phase 1b study demonstrates that miricorilant, a selective cortisol modulator, effectively reduces liver fat, improves liver health and key metabolic and lipid measures and is well-toleratedCorcept will initiate a Phase 2b study in the fourth quarter MENLO PARK, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, today announced topline results from a Phase 1b study evaluating its proprietary cortisol modulator, miricorilant, in patients with presumed non-alcoholic steatohepatitis (NASH). The study, which evaluated a range of doses and dosing schedules of miricorilant, found that patients who received 100 mg of miricorilant orally every Monday and Friday for 12 weeks experienced an approximately 30 percent reduction in liver fat as assessed by MRI-PDFF and showed improvements in liver enzymes and markers of liver disease. These patients also experienced improvements in key metabolic and lipid measures such as HOMA-IR, serum triglycerides and LDL. Importantly, miricorilant was very well-tolerated. Corcept plans to submit these results for presentation at a scientific conference. Corcept will initiate a Phase 2b trial in the fourth quarter to further study this dosing regimen. “Miricorilant is highly active in the liver with a unique mechanism of action and holds great promise for the treatment of NASH,” said Naim Alkhouri, MD, FAASLD, Chief Medical Officer of Arizona Liver Health. “The combination of liver fat reduction, improvement in metabolic and lipid measures and low adverse event rate is compelling. Miricorilant has the potential to be a potent solution for the large patient population with NASH.” About NASH Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD) that afflicts millions of patients and is a leading cause of liver-related mortality. Cortisol modulation may serve as a treatment for NASH since cortisol activity at the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) has been implicated in the development and progression of NAFLD. There are no current medications approved to treat NASH. About Corcept Therapeut...